BR112015003796A2 - composição ansiolítica, formulação e método de uso - Google Patents

composição ansiolítica, formulação e método de uso

Info

Publication number
BR112015003796A2
BR112015003796A2 BR112015003796A BR112015003796A BR112015003796A2 BR 112015003796 A2 BR112015003796 A2 BR 112015003796A2 BR 112015003796 A BR112015003796 A BR 112015003796A BR 112015003796 A BR112015003796 A BR 112015003796A BR 112015003796 A2 BR112015003796 A2 BR 112015003796A2
Authority
BR
Brazil
Prior art keywords
receptor antagonist
premedication
anxiety
nmda receptor
composition
Prior art date
Application number
BR112015003796A
Other languages
English (en)
Inventor
L Weg Stuart
Original Assignee
L Weg Stuart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Weg Stuart filed Critical L Weg Stuart
Publication of BR112015003796A2 publication Critical patent/BR112015003796A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract a method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an nmda receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. the nmda receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. the administration of the nmda receptor antagonist composition is particularly useful as a premedication for adults. tradução do resumo resumo patente de invenção: "composição ansiolítica, formulação e método de uso". a presente invenção refere-se a um método para tratamento, melhora ou prevenção do início de ansiedade em um indivíduo compreendendo administrar a tal indivíduo um antagonista receptor de nmda em uma quantidade que é subanestésica ou hipoanalgésica. o antagonista receptor de nmda pode compreender cetamina e seus sais farmaceuticamente aceitáveis, e é administrado como uma pré-medicação. casos de uso desta maneira incluem administração antes da de um evento causador de ansiedade, tal como um procedimento médico ou dentário. a administração da composição antagonista de receptor de nmda é particularmente útil como uma pré-medicação para adultos.
BR112015003796A 2012-08-23 2013-08-23 composição ansiolítica, formulação e método de uso BR112015003796A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
BR112015003796A2 true BR112015003796A2 (pt) 2017-07-04

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003796A BR112015003796A2 (pt) 2012-08-23 2013-08-23 composição ansiolítica, formulação e método de uso

Country Status (11)

Country Link
US (3) US20140057988A1 (pt)
EP (2) EP3878442A1 (pt)
JP (2) JP6722453B2 (pt)
KR (1) KR20150096370A (pt)
CN (1) CN104902883A (pt)
AU (1) AU2013305580A1 (pt)
BR (1) BR112015003796A2 (pt)
IL (1) IL237340A0 (pt)
MX (1) MX2015002378A (pt)
SG (1) SG11201501292UA (pt)
WO (1) WO2014031975A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073096A (zh) 2013-03-15 2015-11-18 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
CN111297803A (zh) * 2013-03-15 2020-06-19 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
PL2983787T3 (pl) 2013-04-12 2020-04-30 Icahn School Of Medicine At Mount Sinai Sposób leczenia zespołu stresu pourazowego
PT3043785T (pt) 2013-09-13 2021-11-05 Univ Chiba Nat Univ Corp Aplicação de r-cetamina e seu sal como medicamentos
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
MX2017003366A (es) 2014-09-15 2018-02-01 Janssen Pharmaceutica Nv Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265).
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
CA2987909C (en) 2015-06-27 2022-04-26 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
ES2909329T3 (es) * 2015-09-08 2022-05-06 Childrens Hospital Philadelphia Activador no selectivo del receptor metabotrópico de glutamato para el tratamiento del trastorno de déficit de atención
WO2017087691A1 (en) * 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3075038B1 (fr) * 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
RU2020123893A (ru) 2017-12-22 2022-01-24 Янссен Фармасьютикалз, Инк. Эскетамин для лечения депрессии
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
KR20210125984A (ko) 2019-02-22 2021-10-19 하리마카세이 가부시기가이샤 고형 땜납재의 도포 방법, 도포물의 제조 방법, 도포 장치, 및 롤 형상의 고형 땜납재
US20230117657A1 (en) 2019-03-05 2023-04-20 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms
FI3976012T3 (fi) * 2019-05-31 2024-04-05 Afyx Therapeutics As Ketamiinin intranasalinen annostus klusteripäänsärkypotilaille

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
KR20090029690A (ko) * 2006-03-22 2009-03-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 우울증을 치료하기 위한 케타민의 투여 방법
BRPI0809843A2 (pt) * 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
JP2016501828A (ja) 2016-01-21
SG11201501292UA (en) 2015-05-28
WO2014031975A1 (en) 2014-02-27
IL237340A0 (en) 2015-04-30
EP2887930A1 (en) 2015-07-01
US20220160655A1 (en) 2022-05-26
US20180235906A1 (en) 2018-08-23
EP3878442A1 (en) 2021-09-15
US20140057988A1 (en) 2014-02-27
AU2013305580A1 (en) 2015-04-09
JP6722453B2 (ja) 2020-07-15
JP6771512B2 (ja) 2020-10-21
MX2015002378A (es) 2015-09-25
KR20150096370A (ko) 2015-08-24
EP2887930A4 (en) 2016-03-23
CN104902883A (zh) 2015-09-09
JP2018162302A (ja) 2018-10-18

Similar Documents

Publication Publication Date Title
BR112015003796A2 (pt) composição ansiolítica, formulação e método de uso
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR112013033008A2 (pt) "formulação farmacêutica líquida compreendendo nitisinona, seu uso e uso de nitinisona"
BR112013021599A2 (pt) (piridin-4-il)benzilamidas como moduladores alostéricos do nachr alfa 7
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112013001717A2 (pt) tratamento de síndrome de imunodeficiência adquirida (aids) com propriedades antivirais de aloe vera
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
BR112013024791A2 (pt) aclidínio para uso na melhoria da qualidade do sono em pacientes com sintomas respiratórios, composição farmacêutica compreendendo o mesmo e seus usos.
BR112014004732A2 (pt) composto benzotiazolona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]